Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?

Gelijkaardige items

• Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy
  door: Barry W. Hennigan, et al.
  Gepubliceerd in: (2022-01-01)
• Unraveling the Complexities for Antiplatelet Strategies Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
  door: Yasar Sattar, et al.
  Gepubliceerd in: (2024-10-01)
• Risk of Postdischarge Bleeding From Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Among US Black and White Adults
  door: Brittain Heindl, et al.
  Gepubliceerd in: (2022-09-01)
• Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban
  door: T. A. Batyraliev, et al.
  Gepubliceerd in: (2008-12-01)
• Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
  door: Marie Muthspiel, et al.
  Gepubliceerd in: (2022-11-01)